Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models
Authors:
- 1 March 2021
- journal article
- review article
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 170, 214-237
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Allergy and Infectious Diseases (AI138195)
- AstraZeneca
- National Cancer Institute (R01CA246785)
- National Institute of General Medical Sciences (GM114179)
This publication has 305 references indexed in Scilit:
- Gene therapy enters the pharma market: The short story of a long journeyEMBO Molecular Medicine, 2013
- Systemic Gene Delivery in Large Species for Targeting Spinal Cord, Brain, and Peripheral Tissues for Pediatric DisordersMolecular Therapy, 2011
- An Evolved Adeno-associated Viral Variant Enhances Gene Delivery and Gene Targeting in Neural Stem CellsMolecular Therapy, 2011
- Preclinical Safety Evaluation of AAV2-sFLT01— A Gene Therapy for Age-related Macular DegenerationMolecular Therapy, 2011
- Widespread Muscle Expression of an AAV9 Human Mini-dystrophin Vector After Intravenous Injection in Neonatal Dystrophin-deficient DogsMolecular Therapy, 2010
- Aβ-directed Single-chain Antibody Delivery Via a Serotype-1 AAV Vector Improves Learning Behavior and Pathology in Alzheimer's Disease MiceMolecular Therapy, 2010
- Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognitionGene Therapy, 2008
- Novel AAV serotypes for improved ocular gene transferThe Journal of Gene Medicine, 2008
- Fusion Antibody for Alzheimer's Disease with Bidirectional Transport Across the Blood−Brain Barrier and Aβ Fibril DisaggregationBioconjugate Chemistry, 2007
- Anti-Aβ single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's diseaseNeurobiology of Disease, 2006